Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan

Abstract

PERCIST is useful for predicting pathological response and prognosis following NAC in breast cancer patients. However, FDG-PET/CT showed a tendency toward underestimation of the residual tumor, and relatively low specificity and PPV of PERCIST showed that a combination of other imaging modalities would still be needed to predict pCR.

Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT

“…SUVmax was defined as the greatest SUV value for pixels with the highest count within the VOI, with the highest for each used as the representative value of each scan. GI-PET (AZE Co., Ltd., Tokyo, Japan), a commercially available software package able to harmonize SUV values across different PET/CT systems [7], was employed.…”

Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

“…2 . The specific number of studies at risk of bias and reasons were as follows: Five studies presented a moderate risk in selection of participants because of the retrospective study designs, lack of clarity regarding whether the patients were enrolled in a consecutive manner, and/or the unclear inclusion and exclusion criteria [ 12 , 23 , 25 , 26 , 32 ]. All studies were rated as having a low risk of attrition bias.…”

“…For prognostic factor measurement, nine studies had a high risk of bias due to the use of data-dependent cut-off values [ 12 – 14 , 18 , 20 , 24 , 27 , 31 , 32 ]. Regarding outcome measurements, fifteen studies had a moderate risk of bias because the definition or methods for measuring disease recurrence were unclear [ 12 – 16 , 22 – 24 , 26 – 32 ]. Six studies presented a moderate risk of confounding bias as no adjustment for potential confounders was performed [ 12 , 18 , 20 , 21 , 24 , 28 ].…”

“…Of note, %ΔSUVmax is defined as (SUVmax at baseline PET − SUVmax at interim or post-treatment PET) / SUVmax at baseline PET × 100%. The CMR in the included studies was defined as negative FDG uptake [ 21 ], or according to the European Organisation for Research and Treatment of Cancer (EORTC) or Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST) criteria [ 17 , 26 , 30 ]. Regarding the timing of interim assessment, PET or PET/CT were performed after two cycles of NAC in five studies [ 17 – 19 , 30 , 32 ], one cycle in four [ 20 , 21 , 28 , 31 ], and three cycles in two studies [ 13 , 29 ].…”

“…Lower SUVmax was significantly associated with longer DFS in all five studies [ 12 , 17 , 22 , 23 , 25 ]. CMR was correlated with better DFS in three studies [ 16 , 17 , 26 ]; however, CMR was no longer statistically significant after completion of multivariate analyses of the data from two of them [ 17 , 26 ]. Two studies reported that metabolic tumour volume and total lesion glycolysis and their reduction rates on post-treatment PET scans were significant predictors for better DFS [ 22 , 25 ].…”